Apyx Medical Corp insider trading
Every open-market purchase and sale by Apyx Medical Corp's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Does following Apyx Medical Corp’s insiders pay?
From December 6, 2010 to November 15, 2023, 7 insiders reported 11 open-market purchases and 2 sales not made under a pre-set plan in Apyx Medical Corp. Twelve months after each purchase was reported, the shares were −38.1% against the S&P 500 on average (median −38.1%), over 1 purchase with a full year of prices; 0% beat the index. That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on September 1, 2022 into $8,879 by November 2, 2026, −2.8% a year. It held shares 24% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $13,352 (+7.2% a year), and held throughout $20,181 (+18.4%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Goodwin Charles D. II | Chief Executive Officer | 3 | −38.1% (1) | 0% | 0 | — | November 15, 2023 |
| Renn Universal Growth Investment Trust | Director | 3 | — | — | 0 | — | August 29, 2011 |
| Gershon Robert | Chief Executive Officer | 2 | — | — | 0 | — | December 23, 2015 |
| Mccarthy John J. III | Chief CommercializationOfficer | 2 | — | — | 0 | — | August 19, 2016 |
| Citronowicz Moshe | Sr. V.P. of Operations | 1 | — | — | 0 | — | December 23, 2015 |
| Kromer George W | Director | 0 | — | — | 1 | — | June 9, 2011 |
| Pardoll Peter | Director | 0 | — | — | 1 | — | December 6, 2010 |